Edwards Lifesciences Corp

Edwards Lifesciences trades at a 43.6 P/E despite sitting nowhere near its 52-week high, signaling the market still prices in substantial future growth even after a pullback. With RSI at 53.9, the stock occupies neutral technical ground—not oversold, not overbought—suggesting room to move in either direction without obvious mean-reversion pressure. The minimal short interest at 1.84% of float indicates skepticism isn't building, which could be concerning if growth disappoints, or reassuring if execution validates the premium multiple. For a surgical-device company, this valuation demands consistent innovation and market-share gains to justify it relative to more cyclical medtech peers.